PATENT CLAIM ANALYSIS

Application Number: 16047805
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-05
Patent Classification: ["514", "365000"]

Abstract:
Provided herein are methods of cancer treatment by administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its structural analogs to a patient with cancer, for example, prostate, liver, lung, ovarian, breast, skin, colon (or rectum), stomach, pancreatic, kidney, bladder, soft tissue, or cervical cancer.

Claim (Index 6):
The method of  claim 1 , wherein the ITE or structural analog thereof is administered by topical, enteral, or parenteral application.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 95.0
- Lexical Diversity: 1.48077
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15613808', '14961325', '13952030', '13503657', '15509722']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8020630239877595
- 35 USC 102 Novelty (BERT): 0.5966731910937307
- Combined Prediction Score: 0.7815240406983567
- Mean Citation Score: 464.73619
- Max Citation Score: 555.94995
- Similarity Product: 414.0202768500924

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test